Cargando…
Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
Patients with cancer treated with immune checkpoint inhibitors (ICIs) develop immune related adverse events (irAEs), however biomarkers are lacking. We hypothesized that clinicopathologic and laboratory factors would be associated with irAE risk and overall survival (OS) in this population. In a ret...
Autores principales: | Michailidou, Despina, Khaki, Ali Raza, Morelli, Maria Pia, Diamantopoulos, Leonidas, Singh, Namrata, Grivas, Petros |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079370/ https://www.ncbi.nlm.nih.gov/pubmed/33907229 http://dx.doi.org/10.1038/s41598-021-88307-3 |
Ejemplares similares
-
Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021) -
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience
por: Kaur, Aneet, et al.
Publicado: (2019) -
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020) -
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020) -
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)